Page last updated: 2024-11-12
ceramide 3
Description
N-oleoylphytosphingosine : A phytoceramide in which the N-acyl group is specified as oleoyl (9Z-octadecenoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (37)
Synonym |
ceramide iii |
ceramide gl(3) |
100403-19-8 |
4370df050b , |
unii-4370df050b |
ceramide 3 |
einecs 309-560-3 |
burkitt's lymphoma associated glycolipid antigen |
n-octadecanoylphytosphingosine |
ATGQXSBKTQANOH-UWVGARPKSA-N |
n-oleoyl-phytosphingosine |
phcer c18:1(n-9) |
n-oleoylphytosphingosine |
n-oloeoyl-4-hydroxysphinganine |
(9z)-n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]octadec-9-enamide |
n-(9z-octadecenoyl)-(4r)-hydroxysphinganine |
cer(t18:0/18:1n-9) |
n-(9z-octadecenoyl)phytosphingosine |
CHEBI:85204 |
ceramide iiib |
n-oleoyl phytosphingosine |
ceramide np [inci] |
cytomide iiib |
cytomide iiia |
ceramide 3 (retired ) [inci] |
octadecanamide, n-(1,3,4-trihydroxy-2-octadecyl)- |
ceramide np |
Q27158397 |
n-(9z-octadecenoyl)-4-hydroxysphinganine |
DB14111 |
178436-06-1 |
n-((2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl)oleamide |
ceramides mixture |
ceramide 3b |
DTXSID201319096 |
9-octadecenamide, n-[(1s,2s,3r)-2,3-dihydroxy-1-(hydroxymethyl)heptadecyl]-, (9z)- |
AKOS040732785 |
Research Excerpts
Toxicity
Drug Classes (1)
Class | Description |
N-acylphytosphingosine | A ceramide that is phytosphingosine having a fatty acyl group attached to the nitrogen. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (15)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 3 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 11 (73.33) | 29.6817 |
2010's | 1 (6.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 3 (20.00%) | 5.53% |
Reviews | 1 (6.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (73.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |